Sign in Subscribe
United States. Securities and Exchange Commission

Biogen Inc. Submits SEC Filing with 12 Documents

Strategic Insights

— 1 min read

Biogen Inc., a leading biopharmaceutical company, submitted a Form 8-K filing with the U.S. Securities and Exchange Commission (SEC) on June 21, 2022. The filing, available on the SEC's website, reveals 12 documents submitted by the company. This filing is a "current report" that highlights material events or corporate changes of importance to investors. As a biotech industry leader, Biogen's submission is a significant update for the healthcare and biotechnology sectors.

Key Takeaways:

  • The SEC filing, Form 8-K, is a current report that discloses material events or corporate changes.
  • Biogen Inc. submitted the filing on June 21, 2022, with 12 documents attached.
  • The SIC code for Biogen Inc. is 2836, indicating its classification as a biological products company.
  • The filing provides more current information on specified events than Form 10-Q or 10-K reports.
  • Biogen's filing is a key event for the biopharmaceutical and healthcare sectors.
  • The company's address and contact information are listed as 225 Binney Street, Cambridge, MA 02142, with the phone number 781-464-2000.

Statistics:

  • 12 documents were filed with the SEC as part of Biogen Inc.'s Form 8-K submission.
  • The filing is listed with the SEC file number 0001193125-22-177791.
  • The SEC filing provides current information on specified events, set apart from Forms 10-Q or 10-K reports.

Sources:

  • NewsRx, "Biogen Inc. (Form 8-K) SEC Filing June 21, 2022"
  • U.S. Securities and Exchange Commission, "Form 8-K, Biogen Inc.,06/21/2022" (https://www.sec.gov/Archives/edgar/data/875045/0001193125-22-177791-index.html)

Read more